全國服務咨詢熱線：
18860915427
18860915427
產品分類
Product Category詳細介紹
| 品牌 | absin | CAS | 5690-03-9 |
|---|---|---|---|
| 分子式 | C13H10O2 | 純度 | ＞98% |
| 分子量 | 198.22 | 貨號 | abs47028308 |
| 規格 | 10mg | 供貨周期 | 現貨 |
| 主要用途 | is a selective NAD(+)-dependent histone | 應用領域 | 化工,生物產業,農林牧漁,制藥/生物制藥,綜合 |
Splitomicin 5690-03-9
| 產品描述 | |
| 描述 | Splitomicin is a selective NAD(+)-dependent histone deacetylase Sir2p inhibitor with IC50 of 60 μM, showing a higher activity in a cell-based assay. |
| 純度 | ＞98% |
| 儲存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 別名 | 斯普利特麻一辛 |
| 外觀 | Powder |
| 可溶性/溶解性 | DMSO : 19.8 mg/mL (100 mM) Ethanol : 19.8 mg/mL (100 mM) |
| 生物活性 | |
| 靶點 | Sir2p |
| In vitro(體外研究) | Splitomicin inhibits Sir2p deacetylase activity by altering or blocking access to the acetylated histone binding pocket. [1] Splitomicin inhibits platelet aggregation induced by thrombin, collagen, AA and U46619 via inhibition of cyclic AMP phosphodiesterase activity and subsequent inhibition of intracellular Ca(++) mobilization, TXB2 formation and ATP release. |
| In vivo(體內研究) | In a photochemical injury mouse model, splitomicin (80 mg/kg/d i.p.) enhances tissue factor activity in the arterial vessel wall and promotes carotid artery thrombus formation. |
| 參考文獻 | |
| 參考文獻 |
|
| 研究領域 | |
| 研究領域 | CancerCancer Metabolism CancerTumor biomarkers Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產品咨詢
電話
微信掃一掃
地址：上海市浦東新區新浩路58號申江科創園18棟
郵箱：fengmj@univ-bio.com
傳真：